See the DrugPatentWatch profile for lipitor

Lipitor, a medication commonly prescribed to manage high cholesterol, is known to have a high protein binding rate [1]. Protein binding refers to the interaction between a drug and certain proteins in the bloodstream, which can affect the drug's distribution, metabolism, and excretion [2]. However, there is limited information directly linking Lipitor's protein binding to kidney function in patients.

According to DrugPatentWatch.com, Lipitor's primary mechanism of action is the inhibition of HMG-CoA reductase, an enzyme involved in cholesterol production [3]. The drug's protein binding does not seem to have a direct impact on kidney function. Instead, kidney function is more likely to be affected by the drug's metabolites or potential side effects, such as myopathy or rhabdomyolysis, which can lead to kidney damage in severe cases [1][2].

In summary, while Lipitor has a high protein binding rate, there is no substantial evidence to suggest that this directly affects kidney function in patients. It is essential to monitor kidney function during Lipitor treatment, but this is primarily due to potential side effects rather than protein binding [1][2].

Sources:
[1] "Atorvastatin (Lipitor)". Mayo Clinic. <https://www.mayoclinic.org/drugs-supplements/atorvastatin-oral-route/side-effects/drg-20063002>.
[2] "Protein Binding". National Center for Biotechnology Information. <https://www.ncbi.nlm.nih.gov/books/NBK557835/>.
[3] "Lipitor (Atorvastatin Calcium)". DrugPatentWatch.com. <https://www.drugpatentwatch.com/drugs/lipitor>.